Activity from announced rounds
Noshaq is the Belgian investor identified by its own company list and by Novadip and Standing Ovation announcements.
Its recorded companies include Novadip’s regenerative cell therapies, Amyl’s antibodies against amyloid aggregates and Brenus’ off-the-shelf cancer immunotherapy. These programs pursue different clinical mechanisms and retain separate financing records.
A clinical-stage biotechnology company developing regenerative cell therapies and grafts to repair bone and other damaged tissues, including a pivotal-stage treatment for a rare pediatric bone disorder.
Amyl Therapeutics is developing immunotherapies that target amyloid aggregates linked to neurodegenerative disease.